Amplia Therapeutics
Tracked across 3 events · 26 articles · First seen May 09, 2026 · Last active Sep 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Amplia Therapeutics is the developer of narmafotinib and has entered into an agreement with Australia New Zealand Gynaecological Oncology Group (ANZGOG) to conduct a clinical study in ovarian cancer. This study broadens the clinical utility of its FAK inhibitor program.
May 09, 2026 · 8 articles
Business
Impact: Amplia Therapeutics Limited announced changes to its Board leadership, with Dr. Warwick Tong retiring as Chairman and Ms. Jane Bell AM being appointed as the new Board Chair. This is part of a succession plan to prepare for new opportunities.
Jul 06, 2026 · 6 articles
Business
Virtual Investor Conferences, a proprietary investor conference series, announced on September 14, 2026 the agenda for its upcoming Life Sciences Virtual Investor Forum, scheduled for September 17, 2026 in New York. The online event is…
Impact: Amplia Therapeutics is scheduled to present at 2:00 PM ET, allowing it to update investors on its clinical-stage programs.
Sep 14, 2026 · 12 articles
30
Amplia Therapeutics scheduled presentationLife Sciences Virtual...
ERGEN INTELLIGENCE
Track Amplia Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard